CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Average Recommendation of “Moderate Buy” from Brokerages

CytomX Therapeutics, Inc. (NASDAQ:CTMX) has received a consensus recommendation of “Moderate Buy” from the six analysts that are currently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $5.77.

Separately, HC Wainwright reiterated a “neutral” rating on shares of CytomX Therapeutics in a report on Monday, November 11th.

Institutional Trading of CytomX Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. US Bancorp DE acquired a new position in shares of CytomX Therapeutics in the 3rd quarter worth approximately $40,000. SG Americas Securities LLC acquired a new position in CytomX Therapeutics in the first quarter valued at $57,000. XTX Topco Ltd lifted its holdings in CytomX Therapeutics by 382.6% in the second quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company’s stock valued at $74,000 after buying an additional 48,033 shares during the period. Forefront Analytics LLC boosted its position in CytomX Therapeutics by 206.7% during the second quarter. Forefront Analytics LLC now owns 64,065 shares of the biotechnology company’s stock valued at $78,000 after acquiring an additional 43,176 shares during the last quarter. Finally, Cubist Systematic Strategies LLC grew its holdings in CytomX Therapeutics by 96.6% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company’s stock worth $100,000 after acquiring an additional 40,309 shares during the period. 67.77% of the stock is currently owned by institutional investors.

CytomX Therapeutics Stock Performance

CytomX Therapeutics stock opened at $0.89 on Monday. The stock has a fifty day moving average of $1.08 and a 200-day moving average of $1.30. The stock has a market capitalization of $69.65 million, a P/E ratio of 5.24 and a beta of 1.06. CytomX Therapeutics has a 52 week low of $0.83 and a 52 week high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.23. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. The business had revenue of $33.43 million during the quarter, compared to analysts’ expectations of $18.92 million. During the same period in the prior year, the company earned $0.04 EPS. On average, research analysts forecast that CytomX Therapeutics will post -0.13 earnings per share for the current year.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.